Sulphonylureas (e.g., gliclazide) and thiazolidinediones (e.g., pioglitazone) are older oral agents still used in certain situations, though they are less commonly prescribed due to side effect profiles, including weight gain and hypoglycaemia risk
declares associations to Abbott, ADOC Pharma, Alkaloid, AstraZeneca, Bayer, Boehringer-Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris, and Wrwag Pharma
With the development of genetic testing technologies such as genome-wide association studies (GWAS) and next-generation sequencing (NGS), it has been discovered that approximately 127 locus abnormalities in the human genome are associated with the onset and progression of obesity [4] , as along with more than 550 monogenic mutations related to obesity [5]
Traveling during the first few weeks of using GLP1s has added complexity and glucose variability, without a doubt